Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Baxter
Merck
Express Scripts
Moodys

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HABITROL

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Habitrol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00851357 ↗ Telephone Counseling and the Distribution of Nicotine Patches to Smokers Completed California Department of Health Services Phase 3 2009-02-01 The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1. Test if sending active nicotine patches directly will lead to a higher quit rate, compared to a condition where the quitline assists the smokers to obtain patches by other means (e.g. via their health plans). 2. Test if sending placebo patches directly will also lead to a higher quit rate. 3. Test if quitline counseling increases the quit rate when the smokers already receive the nicotine patches.
NCT00851357 ↗ Telephone Counseling and the Distribution of Nicotine Patches to Smokers Completed University of California, San Diego Phase 3 2009-02-01 The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1. Test if sending active nicotine patches directly will lead to a higher quit rate, compared to a condition where the quitline assists the smokers to obtain patches by other means (e.g. via their health plans). 2. Test if sending placebo patches directly will also lead to a higher quit rate. 3. Test if quitline counseling increases the quit rate when the smokers already receive the nicotine patches.
NCT00954096 ↗ Nicotine Patch, Blood Flow and Oxidative Stress Study Completed National Institutes of Health (NIH) N/A 2002-10-01 This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.
NCT00954096 ↗ Nicotine Patch, Blood Flow and Oxidative Stress Study Completed University of Pennsylvania N/A 2002-10-01 This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.
NCT00960778 ↗ Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes Completed Medical University of South Carolina Phase 2 2009-03-01 This study will investigate the underlying neurobiology of differences between male and female smokers. Research suggests that women are less responsive to nicotine replacement therapy (NRT) than men and more responsive to the sensory and behavioral aspects of smoking. This study proposed that male smokers will have a greater response to NRT demonstrated by reduced withdrawal symptoms, craving, and less blood-oxygen-level dependent functional magnetic resonance imaging (BOLD FMRI) regional brain activation in response to nicotine-cues as compared to female smokers treated with NRT. Additionally, female smokers will have a greater response to denicotinized cigarettes with decreased withdrawal symptoms, craving, and less BOLD fMRI activation in response to nicotine-cues as compared to male smokers.
NCT01145001 ↗ Enhancing a High School Based Smoking Cessation Program Completed National Institute on Drug Abuse (NIDA) N/A 2009-11-01 The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (CM) + cognitive behavioral therapy intervention. Subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either CM or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that subjects receiving both active nicotine patch and CM will have higher rates of abstinence from tobacco than subjects in the other groups.
NCT01145001 ↗ Enhancing a High School Based Smoking Cessation Program Completed National Institutes of Health (NIH) N/A 2009-11-01 The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (CM) + cognitive behavioral therapy intervention. Subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either CM or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that subjects receiving both active nicotine patch and CM will have higher rates of abstinence from tobacco than subjects in the other groups.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Habitrol

Condition Name

Condition Name for Habitrol
Intervention Trials
Smoking Cessation 5
Nicotine Dependence 2
Healthy 1
Marijuana Dependence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Habitrol
Intervention Trials
Tobacco Use Disorder 2
Mental Disorders 1
Cardiovascular Diseases 1
Marijuana Abuse 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Habitrol

Trials by Country

Trials by Country for Habitrol
Location Trials
United States 9
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Habitrol
Location Trials
California 3
New York 1
Ohio 1
Illinois 1
Connecticut 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Habitrol

Clinical Trial Phase

Clinical Trial Phase for Habitrol
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Habitrol
Clinical Trial Phase Trials
Completed 9
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Habitrol

Sponsor Name

Sponsor Name for Habitrol
Sponsor Trials
University of California, San Diego 3
National Institute on Drug Abuse (NIDA) 2
California Department of Health Services 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Habitrol
Sponsor Trials
Other 16
NIH 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.